Q32 Bio Inc QTTB.O:
Q32 BIO INC: TO DISCONTINUE RENAL BASKET TRIAL FOR ADX-097 TO CONSERVE RESOURCES
Q32 BIO INC: EVALUATE STRATEGIC OPTIONS FOR ITS TISSUE-TARGETED COMPLEMENT INHIBITOR PLATFORM
Q32 BIO INC: CASH RUNWAY EXPECTED TO EXTEND TO 2H'26
Q32 BIO INC: INITIATING OPEN-LABEL EXTENSION FROM SIGNAL-AA PART A IN 1H'25
Q32 BIO INC: SIGNAL-AA PART B REMAINS ON TRACK FOR INITIATION OF DOSING IN 1H'25, WITH TOPLINE DATA EXPECTED IN 1H'26
Source text: ID:nPn11yPfKa
Further company coverage: QTTB.O
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。